carmustine has been researched along with Seizures in 9 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Seizures: Clinical or subclinical disturbances of cortical function due to a sudden, abnormal, excessive, and disorganized discharge of brain cells. Clinical manifestations include abnormal motor, sensory and psychic phenomena. Recurrent seizures are usually referred to as EPILEPSY or seizure disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU." | 9.10 | Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. ( Barker, F; Bruce, J; Fisher, J; Grossman, SA; Hilt, D; Judy, K; Olivi, A; Olsen, J; Piantadosi, S; Tatter, S, 2003) |
| "Anticonvulsant therapy is usually recommended before surgery in all patients affected by high grade glioma who are planned to be treated with Carmustine 1,3-bis [2 chloroetyl]-1-nitrosurea, or BCNU) wafers." | 5.15 | Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience. ( Ciccarino, P; d'Avella, D; Del Moro, G; Della Puppa, A; Denaro, L; Lombardi, G; Manara, R; Rossetto, M; Rotilio, A; Scienza, R, 2011) |
| "This New Approaches to Brain Tumor Therapy CNS Consortium study sought to determine the maximum-tolerated dose (MTD) of carmustine (BCNU) that can be implanted in biodegradable polymers following resection of recurrent high-grade gliomas and the systemic BCNU exposure with increasing doses of interstitial BCNU." | 5.10 | Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. ( Barker, F; Bruce, J; Fisher, J; Grossman, SA; Hilt, D; Judy, K; Olivi, A; Olsen, J; Piantadosi, S; Tatter, S, 2003) |
| "Factors predicting adverse events following implantation with wafers containing 1,3-bis(2-chloroethyl)-1-nitrosourea (carmustine, BCNU), which is used in local chemotherapy for malignant gliomas (MGs), are unknown." | 4.12 | Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures. ( Fujii, Y; Goto, T; Hanaoka, Y; Hardian, RF; Hongo, K; Horiuchi, T; Kato, H; Ogiwara, T, 2022) |
| "A 35-year-old man presented with partial seizures 10 years after resection of a left-sided glioblastoma multiforme." | 1.30 | Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS. ( Cecil, KM; Hackney, DB; Lenkinski, RE; Pruitt, AA; Quan, D, 1999) |
| "During this period, partial seizures occurred." | 1.27 | Decreased phenytoin level during antineoplastic therapy: a case report. ( Albani, F; Baruzzi, A; Bollini, C; Bollini, P; Cacciari, L; Ida, N; Riva, R, 1983) |
| " Inhibition of this enzyme results in an alteration in sensitivity of the organism to the toxic effects of O2." | 1.27 | Effect of inhibition of glutathione reductase by carmustine on central nervous system oxygen toxicity. ( Powell, SR; Puglia, CD, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 2 (22.22) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Fujii, Y | 1 |
| Ogiwara, T | 1 |
| Kato, H | 1 |
| Hanaoka, Y | 1 |
| Hardian, RF | 1 |
| Goto, T | 1 |
| Hongo, K | 1 |
| Horiuchi, T | 1 |
| Della Puppa, A | 1 |
| Denaro, L | 1 |
| Rossetto, M | 1 |
| Ciccarino, P | 1 |
| Manara, R | 1 |
| Lombardi, G | 1 |
| Del Moro, G | 1 |
| Rotilio, A | 1 |
| d'Avella, D | 1 |
| Scienza, R | 1 |
| Cutts, J | 1 |
| Lee, G | 1 |
| Berarducci, M | 1 |
| Thomas, C | 1 |
| Dempsey, PK | 1 |
| Kadish, SP | 1 |
| Olivi, A | 1 |
| Grossman, SA | 1 |
| Tatter, S | 1 |
| Barker, F | 1 |
| Judy, K | 1 |
| Olsen, J | 1 |
| Bruce, J | 1 |
| Hilt, D | 1 |
| Fisher, J | 1 |
| Piantadosi, S | 1 |
| Bollini, P | 1 |
| Riva, R | 1 |
| Albani, F | 1 |
| Ida, N | 1 |
| Cacciari, L | 1 |
| Bollini, C | 1 |
| Baruzzi, A | 1 |
| Quan, D | 1 |
| Hackney, DB | 1 |
| Pruitt, AA | 1 |
| Lenkinski, RE | 1 |
| Cecil, KM | 1 |
| Gehan, EA | 1 |
| Walker, MD | 1 |
| van Dijk, JM | 1 |
| Sonnenblick, M | 1 |
| Weissberg, N | 1 |
| Rosin, A | 1 |
| Powell, SR | 1 |
| Puglia, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PHASE I, OPEN LABEL, MULTICENTER DOSE ESCALATION STUDY OF GLIADEL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA[NCT00004028] | Phase 1 | 0 participants | Interventional | 1996-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for carmustine and Seizures
| Article | Year |
|---|---|
Postoperative seizure in high grade glioma patients treated with BCNU wafers. A mono-institutional experience.
Topics: Anticonvulsants; Antineoplastic Agents, Alkylating; Brain Neoplasms; Carmustine; Clinical Trials, Ph | 2011 |
Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial.
Topics: Absorbable Implants; Adult; Aged; Antineoplastic Agents, Alkylating; Biocompatible Materials; Brain | 2003 |
Prognostic factors for patients with brain tumors.
Topics: Age Factors; Brain Neoplasms; Carmustine; Clinical Trials as Topic; Female; Humans; Male; Prognosis; | 1977 |
6 other studies available for carmustine and Seizures
| Article | Year |
|---|---|
Cerebral Edema Due to Chemotherapeutic Wafer Implantation for Malignant Glioma: Registry Study of Correlation with Perioperative Epileptic Seizures.
Topics: Adult; Antineoplastic Agents, Alkylating; Brain Edema; Brain Neoplasms; Carmustine; Combined Modalit | 2022 |
Goosebumps.
Topics: Astrocytoma; Brain Neoplasms; Carmustine; Dexamethasone; Diagnosis, Differential; Frontal Lobe; Huma | 2002 |
Decreased phenytoin level during antineoplastic therapy: a case report.
Topics: Antineoplastic Agents; Brain Neoplasms; Carmustine; Drug Interactions; Drug Therapy, Combination; Hu | 1983 |
Transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Brain; Brain Neoplasms; Carmustine; Combi | 1999 |
Pseudohypercalcemia and hyperviscosity with neurological manifestations in multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Blood Viscosity; Carmustine; Cyclophosphamide; | 1986 |
Effect of inhibition of glutathione reductase by carmustine on central nervous system oxygen toxicity.
Topics: Animals; Carmustine; Glucosephosphate Dehydrogenase; Glutathione Reductase; Lomustine; Male; Nitroso | 1987 |